SCM
IPXL

Sigma Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Sigma Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-185,000
Closed -$3.79M – 315
2013
Q3 		$3.79M Buy
185,000
+105,000
+131% +$2.17M 0.16% 160
2013
Q2 		$1.6M Buy
+80,000
New +$1.42M 0.07% 191

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sigma Capital Management's IPXL Position: Q4 2013 in Review

Sigma Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2013, closing a stake of 185,000 shares — an estimated $3.79M sold.

Sigma Capital Management first reported a position in IPXL in Q2 2013 and held it in 2 quarters. The position peaked at $3.79M in Q3 2013. 166 funds tracked by Wall St. Rank hold IPXL as of Q4 2013.

  • Sigma Capital Management reported no remaining Impax Laboratories, Inc. position as of Q4 2013 after selling out during the quarter.
  • Sigma Capital Management sold 185,000 Impax Laboratories, Inc. shares in Q4 2013, an estimated $3.79M.
  • Sigma Capital Management first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 2 quarters.
  • Sigma Capital Management's Impax Laboratories, Inc. position peaked at $3.79M in Q3 2013.
  • 166 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2013.

Based on Sigma Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.